Posts by: Margarida Azevedo

Margarida Azevedo

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

March 30, 2020March 30, 2020

Zevalin Improves Survival of Non-Hodgkin’s Lymphoma Patients in Real-world Setting, Study Finds

News

Treatment with Zevalin (ibritumomab tiuxetan), which combines an antibody with a radioactive agent, was found to be safe, reduced tumor burden in most patients, and significantly improved survival without disease worsening ... Read more

March 19, 2020March 19, 2020

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TG Therapeutics‘ investigational oral therapy umbralisib for the treatment of follicular lymphoma (FL). The status, which follows another ... Read more

March 5, 2020March 5, 2020

Tipifarnib Granted FDA Fast Track Designation for T-cell Lymphomas

News

Kura Oncology‘s investigational lead therapy candidate tipifarnib was given fast track status by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with different subtypes of ... Read more

February 27, 2020February 27, 2020

Corvus’ CPI-818 Shows Promising Early Results in T-cell Lymphomas, Data Finds

News

Twice-daily treatment with Corvus Pharmaceuticals‘ potential therapy for T-cell lymphomas, CPI-818, is showing promising safety and tolerability, and preliminary signs of efficacy, according to Phase 1/1b results. The early clinical ... Read more

February 11, 2020February 11, 2020

FDA Grants Priority Review to Kite’s CAR T-cell Therapy KTE-X19 for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review Kite Pharma’s application requesting the approval of its investigational CAR T-cell therapy KTE-X19 for treating adult patients with relapsed or ... Read more

May 23, 2016May 23, 2016

Action of BET Inhibitors, a Potential and Promising Lymphoma Drug Class, Seen in Study

News

Researchers studying the mechanism of action of BET inhibitors, drugs thought to be of promise in treating blood cancers such as leukemia and lymphoma, report discovering not only how these drugs kill cancer cells but ... Read more

May 17, 2016May 17, 2016

Scientists, Relying on Work from 1980s, Develop a Molecule Seen to Kill B-cell Lymphoma in Mice

News

Stanford University researchers developed a new method, using molecules called peptibodies, to target and clear human lymphoma cells in a mouse model. The approach is a refinement of a quite promising monoclonal antibody that was developed over 30 years ... Read more

April 7, 2016April 7, 2016

Researchers Identify MicroRNA as Potential Target in Very Aggressive B-cell Lymphoma

News

Researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have discovered a potentially new therapeutic target to treat activated B-cell diffuse large B-cell ... Read more

April 6, 2016April 6, 2016

Relapsed Follicular Lymphoma Patients Appear to Benefit from Reduced-Intensity Allogeneic Transplants

News

Researchers have evaluated the efficacy of reduced-intensity allogeneic transplant as a treatment for patients with follicular lymphoma who experience disease recurrence after autologous stem cell transplant, finding it is an effective ... Read more

April 5, 2016April 5, 2016

Lymphoma Linked to Rheumatoid Factor and Disease Activity in Primary Sjögren’s Syndrome Patients

News

Predictive factors for lymphoma development in people with primary Sjögren’s syndrome include the presence of rheumatoid factor and disease activity, in addition to those factors already known, according to research titled “Rheumatoid Factor ... Read more